Mississippi Clinical Trials Report — July 2026

Mississippi residents who may qualify for a clinical trial should begin with the 13 studies expected to close within the next 90 days. None of these closing-soon trials accept healthy volunteers, so patients with the listed conditions have the most time-sensitive opportunities. The state currently has 369 recruiting trials across 39 cities and 229 research sites.

Patients facing near-term enrollment deadlines should act now

The closing-soon studies span urgent and specialized medical needs, including stroke, brain hemorrhage, diabetic foot ulcers, labor induction, dementia, and cancer. Enrollment projections can change, but screening and consent may take time, making early contact with a study site especially important.

• Acute infection, cervical ripening, cervical ripening and induction of labor, vascular dementia, diabetic foot ulcer, induction of birth, intracerebral hemorrhage, ischemic stroke, malignancy, and malignant solid neoplasm are among the conditions represented in the 13 closing-soon trials.
• 0 closing trials accept healthy volunteers.
• Potential participants should confirm current enrollment and ask whether the Mississippi site is still screening.

The range of conditions means the immediate opportunity is not limited to one specialty. People recovering from ischemic stroke or intracerebral hemorrhage, patients with diabetic foot ulcers or cancer, and pregnant patients being evaluated for cervical ripening or induction may all find that timing is critical. A physician, hospital research office, or trial contact can help determine whether a person’s diagnosis, treatment history, and location fit the study.

A standout sickle cell pain study opens in Jackson

Among July’s new trials, the University of Mississippi Medical Center is sponsoring a Phase 4 study of low-dose bolus ketamine for sickle cell pain crisis. NCT07682662 plans to enroll 400 participants and compares ketamine with opioids. The study will examine whether ketamine can reduce the number of admissions needed for continued pain control during a sickle cell pain crisis.

This trial may be particularly relevant for people who experience vaso-occlusive pain episodes and receive care at or near a participating medical center. Because the study is focused on treatment during a serious acute condition, prospective participants and families may need to discuss eligibility with clinicians before or during an eligible pain crisis.

Mississippi also gained a notable industry-sponsored oncology study. Bristol-Myers Squibb is sponsoring NCT07680764, a Phase 2 trial planning to enroll 160 participants with locally advanced or metastatic non-small cell lung cancer. It evaluates Imzokitug combined with Pumitamig and platinum-doublet chemotherapy against Pumitamig and chemotherapy as first-line treatment.

• NCT07682662 — Phase 4 low-dose ketamine study for sickle cell pain crisis; University of Mississippi Medical Center; planned enrollment of 400.
• NCT07680764 — Phase 2 first-line study for locally advanced or metastatic non-small cell lung cancer; Bristol-Myers Squibb; planned enrollment of 160.

These two studies stand out for different reasons: the UMMC study addresses a recurring acute-care challenge in sickle cell disease, while the Bristol-Myers Squibb trial offers an investigational combination approach in advanced lung cancer. Neither study accepts healthy volunteers.

July brought fewer openings, with a strong Mississippi medical focus

Mississippi added 4 new trials in July, down from 9 in June and May’s 9. The recent pattern shows a variable pipeline: 9 new trials opened in February, followed by 8 in March, 4 in April, 8 in May, 9 in June, and 4 in July. The data also show 2 new trials listed for August, suggesting that the pace may remain uneven.

New research covers both serious disease and maternal-child health. The condition listings include breastfeeding, human milk, premature and preterm infant health, vitamin A deficiency, lung cancer screening, and sickle cell disease. Cancer research appears in two separate new-trial categories: locally advanced non-small cell lung cancer and metastatic non-small cell lung cancer.

• Breastfeeding and human milk
• Locally advanced and metastatic non-small cell lung cancer
• Lung cancer screening
• Premature and preterm infant health
• Sickle cell disease and vaso-occlusive pain episodes
• Vitamin A deficiency

Two of the new studies are drug trials. Behavioral research accounts for one, and one is a dietary-supplement study. Another new study falls into an other-intervention category. This combination gives patients options that range from investigational medicines to behavioral or nutrition-related research.

Jackson leads, but new studies reach several Mississippi communities

Jackson is the main center of July’s new activity, with 3 new trials. Hattiesburg follows with 2. Gulfport, Greenville, Greenwood, New Albany, and Tupelo each have 1 new trial.

• Jackson — 3 new trials
• Hattiesburg — 2
• Gulfport, Greenville, Greenwood, New Albany, and Tupelo — 1 each

The geographic pattern is centered on Jackson and Hattiesburg but extends across the state, from the Gulf Coast to the Delta and northeastern Mississippi. The statewide total of 39 recruiting cities and 229 research sites is larger than July’s group of newly opened studies, so residents should search the full recruiting inventory rather than only the newest listings. Some trials may have several sites, while others may require travel to a specialized center.

Who may find an opportunity this month?

None of July’s 4 new trials accept healthy volunteers, although 25 healthy-volunteer trials are recruiting elsewhere in Mississippi. People without a diagnosed condition should therefore search the statewide healthy-participant listings separately instead of relying on the month’s new-trial announcements.

One new trial includes children, which may create an opportunity for families seeking pediatric research. Two new studies include older adults in their eligibility criteria. No July trial is restricted exclusively to women or exclusively to men.

The sponsor mix also reflects Mississippi’s academic and local-care infrastructure. The University of Mississippi Medical Center sponsors 2 of the new trials, while Bristol-Myers Squibb sponsors one and Timothy Mullett sponsors one. Three are classified as other rather than industry-sponsored, and one is industry-sponsored. That balance points to substantial activity from Mississippi-based academic or clinical investigators alongside a major pharmaceutical sponsor.

Patients with sickle cell disease, advanced or screen-detected lung cancer, pregnancy-related needs, infant health concerns, or the conditions represented among the closing studies should contact research sites promptly. Healthy adults still have opportunities among the 25 statewide studies, but July’s new openings are condition-focused. As August approaches, Mississippi’s research landscape may shift again, making regular searches by condition, city, and eligibility the best way to catch the next opening before enrollment narrows.